

**PATELLAR TENDON ENTHESIS ABNORMALITIES AND THEIR ASSOCIATION
WITH KNEE PAIN AND STRUCTURAL ABNORMALITIES IN OLDER ADULTS.**

Authors

Siti Maisarah Mattap¹, Dawn Aitken¹, Karen Wills¹, Andrew Halliday², Changhai Ding^{1,3},
Weiyu Han^{1,3}, Ishanka Munugoda¹, Stephen E Graves⁴, Michelle Lorimer⁵, Flavia Cicuttini⁶,
Graeme Jones¹, Laura L Laslett¹

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania,
Australia;

²Department of Medical Imaging, Royal Hobart Hospital, Hobart, Tasmania, Australia;

³Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou,
China;

⁴Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR),
Adelaide, South Australia, Australia;

⁵South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South
Australia, Australia;

⁶Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
Victoria, Australia.

Corresponding author and person to whom reprint requests should be addressed:

Siti Maisarah Mattap

Menzies Institute for Medical Research,

University of Tasmania,

Private Bag 23

Hobart TAS 7001

Australia;

siti.mattap@utas.edu.au

Co-authors emails

dawn.aitken@utas.edu.au

karen.wills@utas.edu.au

andrew.halliday@ths.tas.gov.au

changhai.ding@utas.edu.au

weiyu.han@utas.edu.au

ishanka.munugoda@utas.edu.au

segraves@aoanjrr.org.au

michelle.lorimer@sahmri.com

flavia.cicuttini@monash.edu

graeme.jones@utas.edu.au

laura.laslett@utas.edu.au

1 **Abstract**

2 **Objective:** To describe associations between presence of patellar tendon enthesis (PTE)

3 abnormalities and symptoms, structural abnormalities, and total knee replacement (TKR) in

4 older adult cohort.

5 **Methods:** PTE abnormalities (presence of abnormal bone signal and/or bone erosion), were

6 measured on T2-weighted magnetic resonance images at baseline in 961 community-

7 dwelling older adults. Knee pain and function limitation were assessed using **Western Ontario**

8 **and McMaster Universities Osteoarthritis Index** (WOMAC). Bone marrow lesions (BMLs),

9 cartilage volume and defects score, and infrapatellar fat pad (IPFP) area were measured using
10 validated methods. Incidence of TKR was determined by data linkage.

11 **Results:** Participants with abnormal PTE bone signal and/or erosion was 20%. Cross-
12 sectionally, presence of PTE abnormalities was associated with greater pain intensity while
13 going up and down stairs ($\beta=0.22$ (95% CI; 0.03, 0.41)), greater risk of femoral BMLs
14 (RR=1.46 (1.12, 1.90)) and worse tibial cartilage defects score (RR=1.70 (1.16, 2.47), and
15 smaller IPFP area ($\beta=-0.27$ (-0.47, -0.06) cm²), after adjustment of confounders.

16 Longitudinally, presence of baseline PTE abnormalities was associated with a deleterious
17 increase in tibial BML size (RR=1.52 (1.12, 2.05)) over 10.7 years but not symptoms, other
18 structural changes, or TKR.

19 **Conclusion:** Patellar tendon enthesis abnormalities are common in older adults. Presence of
20 cross-sectional but not longitudinal associations suggests they are commonly co-exist with
21 other knee structural abnormalities but may not play a major role in symptom development or
22 structural change, excepting tibial BMLs.

23 **Keywords:** patellar tendon enthesis, enthesis abnormalities, enthesopathy, osteoarthritis,
24 MRI, knee

25

26 Introduction

27

28 The signature feature of knee osteoarthritis (OA) is cartilage volume loss; however, OA is a
29 disease of the whole joint [1, 2]. In theory, it can begin in any joint structure, including the
30 attachment site (enthesis) of a ligament and ligaments themselves [3-5].

31

32 Entheses have high tensile strength, enabling them to dissipate mechanical stress during joint
33 movement at the bony interface [6]. The patellar tendon enthesis (PTE) is the attachment site

34 of the ligament, connecting the patella to the tibia. This provides a firm anchor point to keep
35 the patella in position and allow smooth knee bending and straightening [7, 8]. Therefore,
36 abnormalities at the PTE may result in abnormal function and pain, particularly with
37 activities that involve stress on the patellofemoral joint e.g. knee bending, walking up and
38 down stairs. Evidence from histopathological studies of cruciate ligaments in cadavers [9]
39 and magnetic resonance (MR) images of collateral ligament insertions in interphalangeal
40 joints in hand OA [10, 11] demonstrate that abnormal enthesis changes are present in early
41 OA, strengthening the hypothesis that entheses may play a role in OA development.

42

43 While there is evidence for the importance of entheses from histopathology in knees, and MR
44 images in hands, there is no data on associations between knee enthesis abnormalities and
45 pain, physical function, and OA structural abnormalities in vivo, using non-invasive methods.
46 Therefore, we aimed to describe associations between presence of PTE abnormalities visible
47 on MR images and knee pain, physical function limitations, and OA structural abnormalities
48 both cross-sectionally and longitudinally over 2.7 and 10.7 years and incidence of total knee
49 replacement (TKR) over 13.3 years in a cohort of community-dwelling older adults. We
50 hypothesised that presence of PTE abnormalities is associated with knee OA symptoms and
51 structural abnormalities especially knee abnormalities at the patellofemoral compartment.

52 **Method**

53

54 **Participants**

55

56 This study uses data from the Tasmanian Older Adult Cohort (TASOAC) Study. TASOAC is
57 a prospective population-based study. Participants aged between 50 and 80 years were
58 randomly selected from the roll of electors in southern Tasmania (population 229 000), a
59 comprehensive population listing, using sex-stratified simple random sampling without
60 replacement (response rate 57%). Participants attended baseline clinic between March 2002
61 and September 2004 and follow-up clinics at (Phase 2) 2.7 and (Phase 4) 10.7 years later, on
62 average. Additional information was available at 13.3 years through data linkage to the
63 Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).
64 Figure 2 outlines the study timeline. Persons were excluded if they were institutionalised or
65 had contraindications to magnetic resonance imaging (MRI), including metal sutures,
66 presence of shrapnel, iron filings in the eye and claustrophobia.

67 All participants gave written informed consent for the TASOAC study, and the research
68 conducted was in compliance with the Declaration of Helsinki and was approved by the
69 Southern Tasmanian Health and Medical Human Research Ethics Committee.

70 These analyses include 961 participants with baseline MRI (Figure 3), excluding 21 patients
71 whose MR images had artefacts at the PTE sites. Participants with and without baseline MR
72 images had similar demographic profiles (supplementary Table 1), excepting small
73 differences in baseline BMI (mean±SD BMI 27.7 ±4.68 vs 28.9 ±5.13 kg/m²), which were
74 unlikely to be clinically important.

75

76 **MRI**

77

78 MRI scans of the right knee were performed at baseline, 2.7 and 10.7 years. Knees were
79 imaged in the sagittal plane on a 1.5-T Picker unit (Cleveland, Ohio, USA; baseline and 2.7
80 years) and a Siemens unit (Espee, Pennsylvania, USA; 10.7 year). Image sequences
81 included: (1) a T1-weighted fat saturation three-dimensional gradient recall acquisition in the

82 steady state, flip angle 30° , repetition time 31ms, echo time 6.71ms, field of view 16cm, 60
83 partitions, 512×512 -pixel matrix, slice thickness of 1.5mm without an inter-slice gap; (2) a
84 T2-weighted fat saturation two-dimensional fast spin echo, flip angle 90° , repetition time
85 3,067ms, echo time 112ms, field of view 16cm, 15 partitions, 228×256 -pixel matrix, slice
86 thickness of 4mm with a between-slice gap of 0.5 to 1.0mm.

87

88 **PTE abnormalities**

89

90 PTE abnormalities were assessed at baseline on T2-weighted MR images of the right knee,
91 both proximally and distally by one trained observer (SMM), who was trained by a
92 radiologist (AH). Participants with MR imaging artefacts which prevented clear views of
93 PTE sites e.g. alternating bright and dark bands were excluded in the evaluation. As there
94 was no standardised scoring system for PTE abnormalities and adjacent structural
95 abnormalities, we developed a novel scoring system based on a previous study [9]. This
96 system was quick to use, and implementation was straightforward, enabling reproducible
97 scoring for a large number of participants. Features were classified as abnormal signals if the
98 abnormalities were present on more than one consecutive slice. Presence of any abnormality
99 was scored as 1, absence of any abnormality was scored as 0. Quantification abnormality size
100 was not feasible due to image quality. We defined bone signal as an increase in signal
101 intensity (bright abnormal signal) or any abnormal marks at the bone area adjacent to the
102 enthesis site, such as black or white bands and irregular marking next to the cortical bone
103 (Figure 1a and 1b). We defined bone erosion as a sharply bordered dark bone lesion which is
104 visible in two planes with a cortical break seen in at least one plane [12] (Figure 1c and 1d);
105 and tendon signal as an increase in signal intensity of the tendon adjacent to the enthesis
106 (Figure 1e). Deep infrapatellar bursae are fluid-filled sacs at the distal end of the patellar
107 tendon, between the patellar tendon and the tibia; they appear as a hyperintensities on MRI
108 [13] (Figure 1f). Intra-observer reliability was assessed in 20 randomly selected participants
109 after a 2-week interval between the readings using kappa-statistic.
110 The intra-rater agreement was excellent [14] for proximal tendon signal 0.88(95% CI; 0.64 to
111 1.00) distal tendon signal 0.99 (0.97 to 1.00); proximal bone signal 0.72 (0.37 to 1.00) distal

112 bone signal 0.82 (0.80 to 0.99); proximal, distal bone erosion, and deep infrapatellar bursa
113 have small variability to calculate kappa.

114

115 **Pain, physical function limitation, and total WOMAC score**

116

117 Knee pain, physical function limitation, and total WOMAC score were assessed using the
118 self-administered Western Ontario and McMaster Universities Osteoarthritis Index
119 (WOMAC) [15] scale, which was scored using a 10-point numeric rating scale from 0 (no
120 pain, no functional deficit) to 9 (most severe pain, most functional deficit). The WOMAC is a
121 valid knee OA patient reported measures of pain, function limitation, and stiffness [15-17].
122 This study includes 5 components of knee pain and 17 components of function limitation.
123 Participants were asked to rate how much pain, stiffness, and functional deficits they
124 experienced on the day of their questionnaire for their right knee. Knee pain was rated while
125 walking on a flat surface, going up and down stairs, at night while in bed, sitting or lying and
126 standing upright. Each of the pain subscales and physical function subscales are summed to
127 form a score for knee pain (range 0-45), function limitation (range 0-153) and total WOMAC
128 score (pain, physical function, and stiffness) (range 0- 216).

129

130 **Evaluation of cartilage morphology**

131

132 Cartilage defects were assessed by a trained observer at baseline and 2.7 years on T1-
133 weighted MR images (score range, 0 – 4 where 0= normal and 4 indicating full-thickness
134 chondral wear with exposure of subchondral bone), as previously described [18]. Intra-
135 observer repeatability calculated in prior study was excellent (intraclass correlation
136 coefficient (ICC) of 0.80 – 0.94) [18]. Change in cartilage defect score from baseline to
137 follow-up was dichotomised to 0 and 1: 0 representing no change or a decrease in cartilage
138 defects and 1 representing an increase of 1 or more on scale 0 – 4.

139

140 Knee tibial and patellar cartilage volume was measured by a trained observer on T1-weighted
141 MR images at baseline and 10.7 years follow-up by means of image processing on an

142 independent workstation using Osiris software as previously described [18]. The coefficient
143 of variation (CV) was 2.1% for the medial tibia, 2.2% for the lateral tibia, and 2.6% for
144 patella as previously reported [18, 19].

145

146 **Bone marrow lesions**

147

148 Subchondral BMLs were assessed on T2-weighted fat saturation MRI by using OsiriX
149 software at the medial and lateral sites of tibia and femur, and patella. BMLs were defined as
150 areas of increased signal intensity on T2-weighted, located immediately under the articular
151 cartilage. One trained observer scored the BMLs by measuring the maximum area of the
152 lesion at each site in mm² using software cursors at baseline and over 10.7 years follow-up.
153 Baseline and 10.7-year images were read paired with the chronological order known to the
154 reader. Intra-observer reliability using two way mixed-effects model [20] was excellent (0.98
155 (0.96, 0.99)), at baseline and 10.7 years follow-up. A deleterious increase in BML size was
156 defined as any change larger than the least significant criterion (52mm²) [21, 22]; this takes
157 into account measurement error and correlations between BML measurements at baseline and
158 10.7 years of follow-up.

159

160 **Infrapatellar fat pad (IPFP) area**

161

162 Baseline IPFP was measured by manually drawing disarticulation contours around the IPFP
163 boundaries on a section-by-section basis on T2-weighted MR images, using Osiris software
164 (University of Geneva). The maximum area was selected to represent the IPFP size. One
165 observer graded IPFP area on all MRI scans; both intra- and inter-observer reliability
166 calculated in previous study were excellent (ICC = 0.96 for intra-observer reliability, ICC =
167 0.92 for inter-observer reliability) [23].

168

169 **TKR surgery**

170

171 The incidence of primary TKR between 1 March 2002 and 21 September 2016 were
172 determined by data linkage to the AOANJRR. The AOANJRR started data collection in
173 Tasmania in September 2000 and collects data from both public and private hospitals. Data
174 validation against State and Territory Health Department data is done using a sequential
175 multi-level matching proces [24]. Matched data were then obtained which included the date,
176 side of joint replacement, primary or revision joint replacement and the reason for the
177 procedure (e.g., OA, osteonecrosis). In this study, we only considered TKRs that were due to
178 OA.

179 **Additional available baseline data**

180
181 Weight was measured to the nearest 0.1 kg (with shoes, socks, and bulky clothing removed)
182 by using a single pair of electronic scales (Seca Delta Model 707). Height was measured to
183 the nearest 0.1 cm (with shoes and socks removed) by using a stadiometer. Body mass index
184 (BMI) was calculated as kilograms per square meter. A standing anteroposterior semi-flexed
185 view of right knee with 15° of fixed knee flexion was performed and scored individually for
186 osteophytes and joint space narrowing (JSN) on a scale of 0 – 3 [25]. Presence of
187 radiographic osteoarthritis was defined as any score ≥ 1 for JSN or osteophytes.

188
189 Knee extension strength of the dominant leg measured to the nearest kg using a seated
190 isometric contraction of the knee extensors [26]. Meniscal damage was assessed by a trained
191 observer on T1-weighted MR images as previously described [27], and defined as presence
192 of tear or extrusion on the meniscus dichotomised as 0=absent and ≤ 1 =present. Presence of
193 intra-articular fluid-equivalent signal on T2-weighted MRI at the suprapatellar pouch
194 (suprapatellar effusion) was determined as previously described [28].

195 196 **Statistical analysis**

197
198 The primary exposure for all analyses was presence of PTE abnormalities at baseline, defined
199 as presence of abnormal bone signal and/or erosion at PTE.

200

201 As TASSOAC is a community-based cohort, there is a mix of people with and without pain.
202 The pain data is non-normally distributed with a large number of zeros, so exponential hurdle
203 models were the most appropriate model to estimate associations between baseline PTE
204 abnormalities and pain outcomes. The hurdle model has two parts: one model for the
205 presence/absence of pain and a second, separate model for pain severity for those who
206 reported pain. We report estimates from these models separately for each outcome as the
207 relative risk of reporting pain and the coefficient for intensity of pain. The interaction
208 between baseline PTE abnormalities and time was used to calculate estimated change in
209 outcomes over 10.7 years associated with PTE abnormalities. Multivariable models were
210 adjusted for age, sex, BMI, knee extension strength, and additionally adjusted for presence of
211 medial tibiofemoral BMLs, cartilage defects, and suprapatellar effusions.

212

213 Log binomial regression was used to assess associations between presence of PTE
214 abnormalities at baseline and prevalence of BMLs at baseline, deleterious increases in BML
215 size over 10.7 years and risk of TKR incidence over 13.3 years, as well as associations with
216 baseline cartilage defects, and risk of worsening of cartilage defects over 2.7 years. All
217 models were adjusted for age, sex, BMI, and baseline cartilage defects.

218

219 Linear regression was used to estimate associations between PTE abnormalities and
220 infrapatellar fat pad at baseline. The models were adjusted for age, sex, BMI, interaction
221 between age and sex, cartilage defects, and BMLs.

222

223 Multilevel mixed effects regression models were used to estimate associations between PTE
224 abnormalities and cartilage volume loss over 10.7 years. Each model included fixed effect
225 terms for PTE abnormalities at baseline, time (years since baseline), and an interaction term
226 for PTE abnormalities with time. The interaction term estimates the additional change in the
227 outcome per year associated with the presence of PTE abnormalities at baseline. A random
228 intercept was specified for each participant to account for individual differences in baseline
229 cartilage volume, and the correlation between the repeated measurements over time was
230 modelled using an exponential residual variance-covariance structure. Point estimates of

231 change in the cartilage volume loss over 10.7 years were reported for those with PTE
232 abnormalities at baseline compared to those without PTE abnormalities. All models were
233 adjusted for age, sex, BMI, and additionally adjusted for baseline BMLs and cartilage
234 defects.

235

236 All statistical analyses were performed using Stata 15 (Stata-Corp, College Station, Texas,
237 USA). The significant p-value was set at the value of less than 0.05 (two-tailed).

238

Results

239

240

241 Of the 7 abnormalities measured, presence of tendon signal and deep infrapatellar bursa was
242 almost ubiquitous in this group (tendon signal (proximal 97%, distal 84%); deep infrapatellar
243 bursa 93%). Bone signal was infrequent, and bone erosion was rare (bone signal (proximal
244 10%, distal 10%); erosion (proximal 2%, distal 2%)). Prevalence of tendon signal, bone
245 signal, and bone erosion were similar between distal and proximal sites. Therefore, PTE
246 abnormalities were defined as presence of bone signal and/or erosion. At baseline, 20% of
247 participants (n=192/961) had bone signal and/or erosion at the PTE. Of these, 84% had bone
248 signal or erosion at 1 site only, 15% at 2 sites, and <1% at ≥ 3 sites.

249

250 Participants with and without baseline PTE abnormalities had similar demographic and
251 structural profiles (Table 1); however, participants with PTE abnormalities were older, less
252 female, had greater pain, and poorer physical function. They had more OA structural
253 abnormalities (greater proportion of medial and lateral tibiofemoral BMLs, any BMLs, tibial
254 and femoral cartilage defects), compared to participants without PTE abnormalities (Table 1).

255

256 **Associations between PTE abnormalities and knee pain, physical function**
257 **limitation, and total WOMAC score.**

258

259 Presence of PTE abnormalities at baseline was associated with higher risk of presence (vs
260 absence) of pain whilst walking on flat surfaces, going up and down stairs, pain score,
261 function limitations score, and total WOMAC score, in the unadjusted model (Table 2).
262 However, associations remained significant only for presence of pain whilst going up and
263 down stairs and pain score after adjustment for demographic factors but not structural
264 abnormalities.

265

266 PTE abnormalities were associated with greater intensity of function limitation and total
267 WOMAC score in the unadjusted model. This association persisted for physical function
268 limitation after adjustment for demographic factors. Only the association between PTE
269 abnormalities and pain intensity going up and down stairs remained statistically significant
270 after further adjustment for structural abnormalities.

271

272 Longitudinally, presence of baseline PTE abnormalities were not associated with change in
273 risk of presence (vs absence) or intensity of knee pain subscales, pain, physical function
274 limitation, and total WOMAC score over 10.7 years in unadjusted data. Presence of PTE
275 abnormalities at baseline conferred a 3% increase in risk of presence of physical function
276 limitation over 10.7 years, after adjustment of demographic factors and knee extension
277 strength (Table 2) but not after further adjustment for structural abnormalities.

278

279 **Bone marrow lesions**

280

281 Baseline PTE abnormalities were associated with higher risk of presence of tibial and femoral
282 BMLs at baseline after adjustment for demographic confounders (Table 3). The association
283 remained significant for presence of femoral BMLs but associations diminished for tibial
284 BMLs after further adjustment for site-specific cartilage defects (RR=1.27 (95% CI; 0.99,
285 1.62)). PTE abnormalities were not associated with presence of patellar BMLs at baseline.
286 Over 10.7 years, baseline PTE abnormalities conferred a doubling of risk (RR 1.94) of a
287 deleterious tibial BML size increase (change $>52\text{mm}^2$), compared with a participant with no
288 PTE abnormalities; associations persisted after adjustment for demographic and structural
289 factors. PTE abnormalities were not associated with increases in femoral or patellar BML
290 size.

291

292 **Infrapatellar fat pad area**

293

294 Cross-sectionally, PTE abnormalities at baseline were negatively associated with infrapatellar
295 fat pad area, after adjustment for demographic factors (Table 3). This association
296 strengthened after further adjustment for cartilage defects and BMLs.

297

298 **Cartilage defects and volume**

299

300 Participants with PTE abnormalities were more likely to have tibial and femoral cartilage
301 defects at baseline (Table 4). Associations persisted after adjustment for demographic factors,
302 but after adjustment for structural factors (site-specific BMLs), associations only persisted for
303 tibial cartilage defects. PTE abnormalities were not associated with patellar cartilage defects
304 at baseline. Longitudinally, presence of baseline PTE abnormalities were not associated with
305 change of tibial, femoral, and patellar cartilage defect score over 2.7 years. PTE

306 abnormalities were associated with medial tibial cartilage volume loss over 10.7 years after
307 adjustment for demographic factors but not after adjustment of structural factors (RR=1.14
308 (0.84, 1.55)) (Table 4). PTE abnormalities were not associated with cartilage volume loss in
309 other compartments.

310

311 **Total knee replacement**

312

313 Baseline PTE abnormalities were not associated with the incidence of TKR surgery over 13.3
314 years (Table 4).

315 **Discussion**

316

317 This study demonstrates that presence of PTE abnormalities (bone signal and erosion) are
318 associated with greater pain going up and down stairs, presence of femoral BMLs, worse
319 tibial cartilage defect score and lower infrapatellar fat pad area cross-sectionally, independent
320 of structural confounders. However, these associations did not persist longitudinally,
321 excepting associations with increases in tibial BML size. PTE abnormalities were not
322 associated with the change in cartilage defects over 2.7 years, cartilage volume loss over 10.7
323 years, or TKR over 13.3 years. This suggests that PTE abnormalities are not causally related
324 to the knee OA process.

325

326 The prevalence of abnormal changes at the PTE site in our study was 20%, comprising bone
327 signal or erosion at 1 enthesis site (17%), 2 sites (3%) or 3 sites (n=1 person only), assessed
328 reproducibly and non-invasively using MR imaging. This is the first time that such
329 abnormalities have been measured in a similar population; previous studies investigated knee
330 cruciate ligaments, collateral ligaments and tendon of interphalangeal joints. The 2%
331 prevalence of enthesis bone erosion in our sample is larger than 0% (0/18 participants) in
332 MRI images of finger joints of 18 healthy participants (age 30-72) [10], however, this study
333 had both a small sample size and a wide age range. Bone pathology was very common at the
334 cruciate ligament enthesis (range 22% to 69%) assessed using MRI amongst osteoarthritic
335 patients [9], which is consistent with prevalence estimates from our study, also in older adults
336 (10% bone signal at one enthesis site).

337

338 PTE abnormalities were most strongly associated with knee pain going up and down stairs, as
339 expected. This association was independent of demographic and structural covariates. This is
340 the activity where patients first report knee pain [29], and is responsible for the largest stress
341 on hips and knees during weight bearing [30, 31]. Pain while stair climbing can be explained
342 through increase in patellofemoral pressure, lateral tilt, and force distribution on the patella
343 [32]. Our results suggest that PTE abnormalities may be associated with knee pain intensity
344 (possibly anterior knee pain); and that this stress may be associated with the abnormal
345 changes that we see on the enthesis site cross-sectionally. However, the effect size was small
346 and may not clinically important, as associations did not persist longitudinally. This is in
347 contrast with other studies which showed that enthesis abnormalities were related to pain in
348 inflammatory arthritis [33] and heel pain [34-36].

349 We are the first group to explore associations between enthesis abnormalities and joint
350 function. We observed that PTE abnormalities were not associated with presence of
351 functional limitation independent of demographic or structural factors cross-sectionally;
352 however the effect sizes remained similar to pain score. PTE abnormalities were associated
353 with severity of functional limitation after adjustment for demographic factors cross-
354 sectionally, but were not independent of structural covariates. Longitudinally, presence of
355 PTE abnormalities were associated with a small (3%) increase in risk of worsening functional
356 limitation over 10.7 years after adjustment for demographic factors, but this was also not
357 independent of structural factors.

358

359 While almost none of the associations between PTE abnormalities and pain or function were
360 independent of structural factors, we did demonstrate that PTE abnormalities are associated
361 with some structural factors: higher risk of the presence of femoral BMLs at baseline and
362 deleterious increases in tibial BML size over 10.7 years. A weaker cross-sectional association
363 was also seen for tibial BMLs (RR 1.27 (0.99, 1.62)) after full adjustment of covariates at
364 baseline. Previous studies have shown that BMLs can originate from entheses [10, 11], and
365 are commonly adjacent to ligament pathology [37]. Our study design collected data on which
366 compartment the BMLs were in, but not specifically whether the BMLs were or were not
367 adjacent to cruciate ligament enthesis and PTE sites. However, we hypothesise that the
368 observed association is due to the impact of joint loading on the tibia [38, 39]. Ligament
369 degeneration and instability changes the biomechanical joint environment and is one of the
370 risk factors for knee osteoarthritis [40]. The patellar tendon provides joint stability [41], so
371 this association may be due to reduced stability and strength of the patellar tendon
372 attachments.

373

374 Presence of PTE abnormalities was associated with smaller infrapatellar fat pad area, and
375 worse tibial cartilage defects cross-sectionally; but not change in these factors longitudinally.
376 Larger infrapatellar IPFP at baseline is protective for knee pain and cartilage damage in this
377 cohort [23, 42]. We have no longitudinal data on infrapatellar fat pad area.

378

379 The lack of consistency between cross-sectional and longitudinal associations with
380 osteoarthritis outcomes raises questions regarding whether PTE abnormalities are related to
381 osteoarthritis or whether it simply co-occurs with other osteoarthritic structural abnormalities.
382 We also hypothesised that the abnormalities would be more strongly associated with patellar

383 abnormalities, but paradoxically our results showed no association with any patellar
384 abnormalities. Associations between PTE abnormalities and knee pain were seen cross-
385 sectionally but not longitudinally, supporting an absence of longitudinal associations with
386 knee OA structural abnormalities. Tan et al. suggested that enthesopathy-related osteoarthritis
387 could be a specific subcategory of osteoarthritis [43] based on images of interphalangeal
388 joints; however our study suggests that it may not be a major player in development of knee
389 osteoarthritis.

390

391 Strengths of our study include data from a randomly selected community-dwelling cohort,
392 therefore the results can be generalized to community-dwelling older adults. Data collection
393 continued for 10 years, enabling us to assess longitudinal associations. The scoring system
394 used in this study to assess PTE abnormalities is a novel, non-invasive, simple to use, and
395 reproducible system which used T2-weighted fat saturation MRI. Limitations of our study
396 include a lack of standardised scoring system to assess PTE abnormalities, requiring us to
397 develop one from the literature to suit our study. We were unable to measure the size or
398 volume of deep infrapatellar bursae and presence of enthesophytes due to the available image
399 quality. Better image quality would improve the sensitivity of the analysis; since we are
400 unable to assess volume, this may underestimate the magnitude of any associations, as bursa
401 size more than 2-3mm is considered abnormal [44].

402

403 **Conclusions**

404

405 Patellar tendon entheses abnormalities are common in older adults. Presence of cross-
406 sectional but not longitudinal associations suggests they commonly co-exist with other knee
407 structural abnormalities, and they may be a marker of loading manifested through BMLs.
408 However, they may not play a major role in symptom development or structural change with
409 the exception of tibial BMLs.

410

411 **DECLARATIONS**412 **Ethics approval and consent to participate**

413 All research conducted was in compliance with the Declaration of Helsinki and was approved
414 by the Southern Tasmanian Health and Medical Human Research Ethics Committee. All
415 TASOAC participants gave informed written consent at the start of the TASOAC study.

416 **Consent for publication**

417 Not applicable

418 **Availability of data and material**

419 The datasets used and/or analysed during the current study are available from the
420 corresponding author on reasonable request.

421 **Acknowledgements**

422 We thank the participants who made this study possible, and Catrina Boon and Pip Boon
423 for their role in collecting the data, and Jason Rogers for his expertise in enthesal pain.

424 **Author's contributions**

425 All authors were involved in drafting the article or revising it for important intellectual
426 content. All authors have approved the final manuscript. Laura L Laslett
427 (laura.laslett@utas.edu.au) takes responsibility for the integrity of the work as a whole, from
428 inception to finished article.

429 **Conception and design:** Mattap, Aitken, Wills, Halliday, Cicuttini, Jones, Laslett

430 **Analysis and interpretation of data:** Mattap, Aitken, Wills, Jones, Laslett

431 **Drafting of the article:** Mattap

432 **Critical revision of the article for important intellectual content:** Mattap, Aitken, Wills,
433 Halliday, Ding, Han, Munugoda, Graves, Lorimer, Cicuttini, Jones, Laslett

434 **Final approval of the article:** Mattap, Aitken, Wills, Halliday, Ding, Han, Munugoda,
435 Graves, Lorimer, Cicuttini, Jones, Laslett

436 **Statistical expertise:** Wills

437 **Obtaining of funding:** Cicuttini, Jones

438 **Collection and assembly of data:** Mattap, Ding, Munugoda, Graves, Lorimer, Han

439 **Role of funding source**

440 This work was supported by the National Health and Medical Research Council of Australia;
441 Tasmanian Community Fund; Masonic Centenary Medical Research Foundation; Royal
442 Hobart Hospital Research Foundation; and Arthritis Foundation of Australia. The study

443 sponsor had no role in the design of the study; the collection, analysis, and interpretation of
444 the data; or the writing of the article and the decision to submit it for publication.

445 SM Mattap is supported by the Farrell foundation elite postgraduate scholarship, G Jones and
446 LL Laslett are supported by National Health and Medical Research Council. The researchers
447 work independently of their funders.

448 **Competing interest statement**

449 The authors declare no competing interest.

450

Reference List

1. Lane NE, Brandt K, Hawker G, Peeva E, Schreyer E, Tsuji W, et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. *Osteoarthritis Cartilage* 2011; 19: 478-482.
2. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: A disease of the joint as an organ. *Arthritis Rheum.* 2012; 64: 1697-1707.
3. Quasnicka HL, Anderson-MacKenzie JM, Tarlton JF, Sims TJ, Billingham ME, Bailey AJ. Cruciate ligament laxity and femoral intercondylar notch narrowing in early-stage knee osteoarthritis. *Arthritis Rheum.* 2005; 52: 3100-3109.
4. Anderson-MacKenzie JM, Billingham ME, Bailey AJ. Collagen remodeling in the anterior cruciate ligament associated with developing spontaneous murine osteoarthritis. *Biochem. Biophys. Res. Commun.* 1999; 258: 763-767.
5. Setton LA, Elliott DM, Mow VC. Altered mechanics of cartilage with osteoarthritis: Human osteoarthritis and an experimental model of joint degeneration. *Osteoarthritis Cartilage* 1999; 7: 2-14.
6. Benjamin M, Ralphs JR. Fibrocartilage in tendons and ligaments — an adaptation to compressive load. *J. Anat.* 1998; 193: 481-494.
7. Lu HH, Thomopoulos S. Functional Attachment of Soft Tissues to Bone: Development, Healing, and Tissue Engineering. *Annu Rev Biomed Eng* 2013; 15: 201-226.
8. Basso O, Johnson D, Amis A. The anatomy of the patellar tendon. *Knee Surg. Sports Traumatol. Arthrosc.* 2001; 9: 2-5.
9. Binks DA, Bergin D, Freemont AJ, Hodgson RJ, Yonenaga T, McGonagle D, et al. Potential role of the posterior cruciate ligament synovio-entheseal complex in joint effusion in early osteoarthritis: a magnetic resonance imaging and histological evaluation of cadaveric tissue and data from the Osteoarthritis Initiative. *Osteoarthritis Cartilage* 2014; 22: 1310-1317.
10. Tan AL, Grainger AJ, Tanner SF, Shelley DM, Pease C, Emery P, et al. High-resolution magnetic resonance imaging for the assessment of hand osteoarthritis. *Arthritis Rheum.* 2005; 52: 2355-2365.
11. Tan AL, Toumi H, Benjamin M, Grainger AJ, Tanner SF, Emery P, et al. Combined high-resolution magnetic resonance imaging and histological examination to explore the role of ligaments and tendons in the phenotypic expression of early hand osteoarthritis. *Ann. Rheum. Dis.* 2006; 65: 1267-1272.
12. Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. *J. Rheumatol.* 2003; 30: 1385-1386.
13. Chatra PS. Bursae around the knee joints. *Indian J. Radiol. Imaging* 2012; 22: 27-30.
14. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977; 33: 159-174.
15. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J. Rheumatol.* 1988; 15: 1833-1840.
16. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. *Arthritis Care Res. (Hoboken)* 2001; 45: 453-461.
17. White DK, Master H. Patient Reported Measures of Physical Function in Knee Osteoarthritis. *Rheum. Dis. Clin. North Am.* 2016; 42: 239-252.

18. Ding C, Garnero P, Cicuttini F, Scott F, Cooley H, Jones G. Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. *Osteoarthritis Cartilage* 2005; 13: 198-205.
19. Zhu Z, Ding C, Jin X, Antony B, Han W, Laslett LL, et al. Patellofemoral Bone Marrow Lesions: Natural History and Associations With Pain and Structure. *Arthritis Care Res. (Hoboken)* 2016; 68: 1647-1654.
20. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol. Bull.* 1979; 86: 420-428.
21. Dore D, Quinn S, Ding C, Winzenberg T, Zhai G, Cicuttini F, et al. Natural history and clinical significance of MRI-detected bone marrow lesions at the knee: a prospective study in community dwelling older adults. *Arthritis Res. Ther.* 2010; 12: R223.
22. Nguyen TV, Eisman JA. Assessment of Significant Change in BMD: A New Approach. *J. Bone Miner. Res.* 2000; 15: 369-370.
23. Han W, Cai S, Liu Z, Jin X, Wang X, Antony B, et al. Infrapatellar fat pad in the knee: is local fat good or bad for knee osteoarthritis? *Arthritis Res. Ther.* 2014; 16: R145.
24. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report - 2016. Adelaide 2016.
25. Altman RD, Hochberg M, Murphy WA, Jr., Wolfe F, Lequesne M. Atlas of individual radiographic features in osteoarthritis. *Osteoarthritis Cartilage* 1995; 3 Suppl A: 3-70.
26. Scott D, Blizzard L, Fell J, Jones G. Prospective study of self-reported pain, radiographic osteoarthritis, sarcopenia progression, and falls risk in community-dwelling older adults. *Arthritis Care Res. (Hoboken)* 2012; 64: 30-37.
27. Berthiaume MJ, Raynald JP, Martel-Pelletier J, Labonte F, Beaudoin G, Bloch DA, et al. Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging. *Ann. Rheum. Dis.* 2005; 64: 556-563.
28. Wang X, Jin X, Han W, Cao Y, Halliday A, Blizzard L, et al. Cross-sectional and Longitudinal Associations between Knee Joint Effusion Synovitis and Knee Pain in Older Adults. *J. Rheumatol.* 2016; 43: 121-130.
29. Hensor EM, Dube B, Kingsbury SR, Tennant A, Conaghan PG. Toward a clinical definition of early osteoarthritis: onset of patient-reported knee pain begins on stairs. Data from the osteoarthritis initiative. *Arthritis Care Res.* 2015; 67: 40-47.
30. Andriacchi TP, Andersson GB, Fermier RW, Stern D, Galante JO. A study of lower-limb mechanics during stair-climbing. *JBJS* 1980; 62: 749-757.
31. Costigan PA, Deluzio KJ, Wyss UP. Knee and hip kinetics during normal stair climbing. *Gait Posture* 2002; 16: 31-37.
32. Goudakos IG, König C, Schöttle PB, Taylor WR, Singh NB, Roberts I, et al. Stair climbing results in more challenging patellofemoral contact mechanics and kinematics than walking at early knee flexion under physiological-like quadriceps loading. *J. Biomech.* 2009; 42: 2590-2596.
33. Kiris A, Kaya A, Ozgocmen S, Kocakoc E. Assessment of enthesitis in ankylosing spondylitis by power Doppler ultrasonography. *Skeletal Radiol.* 2006; 35: 522-528.
34. Williams SK, Brage M. Heel pain—plantar fasciitis and Achilles enthesopathy. *Clin. Sports Med.* 2004; 23: 123-144.
35. Hyslop E, McInnes IB, Woodburn J, Turner DE. Foot problems in psoriatic arthritis: high burden and low care provision. *Ann. Rheum. Dis.* 2010; 69: 928.

36. Olivieri I, Barozzi L, Padula A, De Matteis M, Pierro A, Cantini F, et al. Retrocalcaneal bursitis in spondyloarthropathy: assessment by ultrasonography and magnetic resonance imaging. *J. Rheumatol.* 1998; 25: 1352-1357.
37. Hernandez-Molina G, Guermazi A, Niu J, Gale D, Goggins J, Amin S, et al. Central bone marrow lesions in symptomatic knee osteoarthritis and their relationship to anterior cruciate ligament tears and cartilage loss. *Arthritis Rheum.* 2008; 58: 130-136.
38. Beckwée D, Vaes P, Shahabpour M, Muyldermans R, Rommers N, Bautmans I. The Influence of Joint Loading on Bone Marrow Lesions in the Knee: A Systematic Review With Meta-analysis. *Am. J. Sports Med.* 2015; 43: 3093-3107.
39. Bennell KL, Creaby MW, Wrigley TV, Bowles K-A, Hinman RS, Cicuttini F, et al. Bone marrow lesions are related to dynamic knee loading in medial knee osteoarthritis. *Ann. Rheum. Dis.* 2010; 69: 1151-1154.
40. Øiestad BE, Engebretsen L, Storheim K, Risberg MA. Knee Osteoarthritis after Anterior Cruciate Ligament Injury. *Am. J. Sports Med.* 2009; 37: 1434-1443.
41. Loudon JK. Biomechanics and Pathomechanics of the Patellofemoral Joint. *Int. J. Sports Phys. Ther.* 2016; 11: 820-830.
42. Pan F, Han W, Wang X, Liu Z, Jin X, Antony B, et al. A longitudinal study of the association between infrapatellar fat pad maximal area and changes in knee symptoms and structure in older adults. *Ann. Rheum. Dis.* 2015; 74: 1818-1824.
43. McGonagle D, Tan AL, Carey J, Benjamin M. The anatomical basis for a novel classification of osteoarthritis and allied disorders. *J. Anat.* 2010; 216: 279-291.
44. McCarthy CL, McNally EG. The MRI appearance of cystic lesions around the knee. *Skeletal Radiol.* 2004; 33: 187-209.

Tables

Table 1. Characteristics of participants divided by presence of PTE abnormalities at baseline (n=961).

	No PTE abnormalities n=769	PTE abnormalities n=192
Age	62.5 (7.1)	64.4 (8.2)
Female sex (%)	53	43
Body Mass Index (kg/m ²)	27.6 (4.6)	28.2 (4.8)
Knee Extension (kg)	30.2 (11.1)	30.2 (11.7)
Radiographic OA (%)	60	57
Any meniscal tears (%)	99.5	100
Any meniscal extrusion (%)	24	28
Suprapatellar effusion (%)	43	39
Any BMLs (%)	52	68
Tibial cartilage defects (%)	18	27
Femoral cartilage defects (%)	25	34
Any cartilage defects (%)	52	59
Infrapatellar fat pad area (cm ²)	7.6 (1.2)	7.6 (1.2)
Cartilage volume (cm ³)		
Medial tibial	22.8 (6.1)	23.5 (6.2)
Lateral tibial	27.3 (7)	28.3 (7.4)
Patellar	32.1 (9.6)	31.9 (9.1)
Medial femoral	40.5 (11.3)	40 (10.4)
Lateral femoral	44.7 (12.6)	45 (12.6)
WOMAC scales		
Pain (0-45)	3.3 (5.9)	4.4 (7.0)
Function limitation (0-153)	9.9 (19.6)	14.9 (25.1)
Total score (0-216)	14.7 (26.8)	21.5 (34.5)

Mean (SD) except for percentages.

Baseline any cartilage defects score was dichotomised to normal/focal blistering (0 and 1) and any loss of chondral thickness (2 or more).

Suprapatellar effusion was dichotomised to normal (0 and 1) and pathological effusion as any score of ≥ 2 .

n, number; BMI, body mass index; OA, osteoarthritis; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

Table 2. Associations of PTE abnormalities and pain, function limitation, and total WOMAC score at baseline and change over 10.7 years.

	Univariable		Multivariable 1		Multivariable 2	
	Present/absent RR (95% CI)	Intensity β (95% CI)	Present/absent RR (95% CI)	Intensity β (95% CI)	Present/absent RR (95% CI)	Intensity β (95% CI)
<i>Baseline (n=961)</i>						
Pain subscales						
Walking on flat surface	1.24 (1.00, 1.52)	0.10 (-0.06, 0.27)	1.18 (0.96, 1.46)	0.11 (-0.06, 0.28)	1.20 (0.90, 1.61)	0.15 (-0.08, 0.38)
Going up and down stairs	1.26 (1.03, 1.54)	0.14 (0.00, 0.29)	1.25 (1.02, 1.54)	0.12 (-0.03, 0.26)	1.20 (0.91, 1.58)	0.22 (0.03, 0.41)
At night while in bed	1.09 (0.89, 1.34)	-0.12 (-0.31, 0.07)	1.04 (0.84, 1.29)	-0.15 (-0.34, 0.04)	0.97 (0.72, 1.32)	-0.07 (-0.34, 0.20)
Sitting or lying	1.22 (0.99, 1.50)	0.02 (-0.16, 0.20)	1.17 (0.95, 1.46)	-0.01 (-0.19, 0.18)	1.05 (0.77, 1.42)	0.03 (-0.23, 0.28)
Standing upright	1.17 (0.95, 1.44)	0.10 (-0.08, 0.28)	1.11 (0.90, 1.38)	0.09 (-0.09, 0.27)	0.98 (0.73, 1.33)	0.18 (-0.07, 0.43)
Pain score	1.26 (1.03, 1.54)	0.11 (-0.10, 0.31)	1.24 (1.01, 1.53)	0.06 (-0.14, 0.26)	1.17 (0.88, 1.54)	0.14 (-0.13, 0.41)
Function limitation score	1.25 (1.02, 1.53)	0.35 (0.08, 0.61)	1.20 (0.97, 1.48)	0.26 (0.01, 0.52)	1.21 (0.91, 1.60)	0.27 (-0.08, 0.62)
Total WOMAC score	1.23 (1.00, 1.51)	0.29 (0.04, 0.55)	1.18 (0.95, 1.46)	0.22 (-0.02, 0.47)	1.12 (0.84, 1.49)	0.29 (-0.05, 0.63)
<i>Change over 10.7 years</i>						
Pain subscales						
Walking on flat surface	1.00 (0.97, 1.03)	0.00 (-0.03, 0.03)	1.00 (0.97, 1.03)	0.00 (-0.03, 0.03)	0.99 (0.96, 1.03)	0.01 (-0.03, 0.04)
Going up and down stairs	1.00 (0.97, 1.03)	-0.01 (-0.03, 0.02)	1.00 (0.97, 1.03)	-0.01 (-0.03, 0.02)	0.99 (0.95, 1.03)	-0.01 (-0.04, 0.02)
At night while in bed	1.02 (0.99, 1.05)	0.01 (-0.02, 0.05)	1.02 (0.99, 1.05)	0.01 (-0.02, 0.05)	1.03 (0.99, 1.06)	0.02 (-0.02, 0.05)
Sitting or lying	1.00 (0.97, 1.03)	0.02 (-0.02, 0.05)	1.00 (0.97, 1.03)	0.02 (-0.01, 0.06)	1.02 (0.98, 1.05)	0.02 (-0.01, 0.06)
Standing upright	1.02 (0.99, 1.05)	-0.01 (-0.04, 0.03)	1.02 (0.99, 1.06)	0.00 (-0.03, 0.03)	1.03 (0.99, 1.07)	0.00 (-0.03, 0.04)
Pain score	1.01 (0.98, 1.04)	-0.01 (-0.05, 0.02)	1.01 (0.98, 1.04)	-0.01 (-0.05, 0.02)	1.01 (0.97, 1.04)	-0.01 (-0.05, 0.03)
Function limitation score	1.03 (1.00, 1.06)	-0.03 (-0.07, 0.01)	1.03 (1.00, 1.06)	-0.03 (-0.07, 0.00)	1.02 (0.98, 1.06)	-0.03 (-0.07, 0.02)
Total WOMAC score	1.02 (0.99, 1.05)	-0.01 (-0.05, 0.03)	1.02 (0.99, 1.06)	-0.01 (-0.05, 0.02)	1.02 (0.98, 1.06)	0.02 (-0.06, 0.02)

Bold denotes p-value<0.05

Multivariable 1- adjusted for age, sex, BMI, knee extension strength

Multivariable 2 – further adjusted for presence of medial tibiofemoral BMLs, cartilage defects, and suprapatellar effusion.

Hurdle model was used to report the association of PTE abnormalities and present/absent and intensity of the outcomes compared with participants without PTE abnormalities. Change over 10.7 years is the estimated change in outcomes over 10.7 years associated with PTE abnormalities.

Table 3. Associations of baseline PTE abnormalities and presence of baseline BMLs, increase in BML size >52mm² over 10.7 years, and baseline infrapatellar fat pad area.

	Univariable	Multivariable 1	Multivariable 2
<i>Baseline presence of BML (n=647) (RR (95%CI))</i>			
Tibial	1.58 (1.24, 2.01)	1.41 (1.10, 1.80)	1.27 (0.99, 1.62)
Femoral	1.79 (1.35, 2.39)	1.68 (1.25, 2.24)	1.46 (1.12, 1.90)
Patellar	1.21 (0.86, 1.71)	1.25 (0.88, 1.77)	1.17 (0.89, 1.55)
<i>Increase in BML size >52mm² over 10.7 years (n=489) (RR (95%CI))</i>			
Tibial	1.94 (1.43, 2.63)	1.94 (1.42, 2.65)	1.52 (1.12, 2.05)
Femoral	1.19 (0.81, 1.73)	1.14 (0.78, 1.67)	1.04 (0.74, 1.48)
Patellar	1.67 (0.91, 3.04)	1.64 (0.91, 2.95)	1.27 (0.73, 2.22)
<i>Baseline Infrapatellar fat pad area (n=961) (β (95% CI))</i>			
	-0.03 (-0.21, 0.16)	-0.20 (-0.35, -0.05)	-0.27 (-0.47, -0.06)

Bold denotes p-value<0.05

Multivariable 1– adjusted for age, sex, and BMI. Baseline infrapatellar fat pad were also adjusted for interaction of age and sex.

Multivariable 2– baseline presence of BMLs and BML size change >52mm² over 10.7 years were further adjusted for baseline cartilage defects, and baseline BMLs for change in BML size. Baseline infrapatellar fat pad were further adjusted for cartilage defects and BMLs.

Baseline BML and increase in BML size were assessed using log binomial model. Baseline IPFP were assessed using linear regression.

Table 4. Association of baseline PTE abnormalities and baseline cartilage defects, improved/worsening of cartilage defects over 2.7 years, cartilage volume over 10.7 years and TKR incident over 13.3 years.

	Univariable	Multivariable 1	Multivariable 2
<i>Baseline cartilage defects (n=961) (RR (95% CI))</i>			
Tibial	1.73 (1.28, 2.34)	1.47 (1.09, 1.97)	1.70 (1.16, 2.47)
Femoral	1.44 (1.12, 1.85)	1.28 (1.01, 1.64)	1.14 (0.84, 1.55)
Patellar	1.15 (0.96, 1.38)	1.07 (0.90, 1.29)	0.97 (0.77, 1.21)
<i>Worsening of cartilage defects over 2.7 years (n=419) (RR (95% CI))</i>			
Tibial	0.94 (0.60, 1.47)	0.90 (0.56, 1.44)	0.81 (0.51, 1.29)
Femoral	1.27 (0.96, 1.67)	1.20 (0.90, 1.59)	1.12 (0.83, 1.51)
Patellar	0.76 (0.48, 1.22)	0.78 (0.49, 1.25)	0.80 (0.50, 1.29)
<i>Change in cartilage volume over 10.7 years (n=481) (β (95% CI))</i>			
Medial tibial	-42.39 (-83.71, -1.07)	-42.18 (-83.50, -0.87)	-39.40 (-81.79, 3.00)
Lateral tibial	-25.44 (-176.99, 126.12)	-24.12 (-175.67, 127.42)	-15.61 (-171.48, 140.25)
Tibial	-213.27 (-466.07, 39.52)	-211.10 (-463.86, 41.66)	-186.22 (-446.04, 73.61)
Patellar	-58.49 (-198.51, 81.53)	-58.33 (-198.34, 81.69)	-47.53 (-192.54, 97.48)
<i>Total knee replacement surgery over 13.3 years (n=961) (RR (95% CI))</i>			
Right knee (n=40)	1.55 (0.78, 3.10)	1.42 (0.71, 2.85)	1.61 (0.64, 4.05)
Left knee (n=42)	1.42 (0.71, 2.83)	1.23 (0.63, 2.40)	0.91 (0.36, 2.29)
Any TKR (n=65)	1.37 (0.79, 2.37)	1.22 (0.71, 2.10)	1.01 (0.49, 2.08)

Multivariable 1– adjusted for age, sex, and BMI




Multivariable 2– baseline cartilage defects were further adjusted for BMLs. Worsening of cartilage defect, change in cartilage volume loss, and TKR were further adjusted for baseline BMLs and cartilage defects.


Baseline and worsening of cartilage defects were assessed using log binomial regression. Change in cartilage volume were assessed using mixed model; β -coefficient represents 1mm³ change in cartilage volume over 2.7 years for those with PTE abnormalities compared to those without PTE abnormalities. Incident of TKR were assessed using log binomial regression.


Figure 1. Patellar tendon and enthesis (PTE) abnormalities measured on T2-w FSE MRI, indicated by white arrows. 1a shows bone signal (increased signal intensity) at the proximal end of PTE and 1b shows bone signal (increased signal intensity with black band) at the distal end of PTE. 1c shows bone erosion at the proximal end of PTE and 1d shows bone erosion at the distal end of PTE. 1e shows proximal and distal tendon signal, while 1f shows presence of deep infrapatellar bursae between the tibia, distal PTE and infrapatellar fat pad. Note: Tendon signal abnormalities and deep infrapatellar bursa were ubiquitous abnormalities and thus were not included in the scoring system for PTE abnormalities


Figure 2. Study time line.

Figure 3. Flow of study participants. n=number of participants included in the analysis.









Supplementary table.

Table 5. The demographic differences between participants included and excluded (without MRI scans (n=116) and artefacts at PTE sites (n=21)) in this study analysis at baseline.

	Participants with MRI (n=961)	Participant without MRI (n=137)	p-value
Age	62.9 (7.4)	64.1 (8.2)	0.086
Female sex (%)	51	53	0.732
BMI (kg/m ²)	27.7 (4.7)	28.9 (5.1)	0.006
Knee Extension (kg)	30.2 (11.2)	28.3 (10.9)	0.060
Radiographic OA (%)	59	60	0.878

Mean(SD) except for percentages.